Welcome to our dedicated page for Celanese Del SEC filings (Ticker: CE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Celanese Corporation (NYSE: CE) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Form 8-K current reports and other documents filed with the U.S. Securities and Exchange Commission. Celanese is a global specialty materials and chemical company in the basic organic chemical manufacturing industry, and its filings offer detailed insight into its financing activities, governance developments and operational decisions.
Recent Form 8-K filings describe a range of material events. Several filings outline registered offerings of senior notes by Celanese US Holdings LLC, a wholly owned subsidiary, including 7.000% Senior Notes due 2031 and 7.375% Senior Notes due 2034. These filings explain that net proceeds are used to repay borrowings under a five-year term loan credit agreement due 2027, fund cash tender offers for outstanding senior notes due 2027 and 2028, and support general corporate purposes, which may include repayment of other indebtedness.
Other 8-K reports cover cash tender offers for the company’s 6.665% Senior Notes due 2027 and 6.850% Senior Notes due 2028, including announcements of the commencement of tender offers, early results and increases in the maximum tender amount and series cap. Additional filings detail a revolving credit agreement providing a five-year unsecured revolving credit facility and an amendment to an existing term loan credit agreement, including new covenant terms.
Celanese filings also document operational and portfolio actions, such as the intended closure of an acetate tow production facility in Lanaken, Belgium, with associated expected non-cash accelerated depreciation and other shutdown costs, and the signing of a purchase and sale agreement to divest the Micromax® portfolio of products. Governance-related filings include the resignation of a Board member and the company’s explanation that the departure was not due to any disagreement on operations, policies or practices.
On Stock Titan, these SEC filings are presented with real-time updates from EDGAR and AI-powered summaries that help explain the key points of each document. Users can quickly understand the implications of Celanese’s 8-K disclosures, senior note offerings, credit agreements, tender offers and other reported events without reading every technical detail.
Timothy Go, a director of Celanese Corporation (CE), reported two open-market purchases of Common Stock on 09/08/2025. The Form 4 shows 500 shares bought at $46.33 and 539 shares bought at $46.175, leaving him with 4,415 total shares beneficially owned after the transactions. The filing was signed by an attorney-in-fact on 09/09/2025.
Mark Christopher Murray, reported as an officer (SVP - Acetyls) of Celanese Corporation (CE), acquired 2,017 shares of Celanese common stock on 08/14/2025 at a reported price of $41.83 per share. Following the transaction the filing reports 17,000 shares beneficially owned in a direct ownership form. The Form 4 was signed by an attorney-in-fact on 08/18/2025. No derivative transactions are reported on this filing.
Celanese Corporation (CE) director Scott McDougald reported a non-derivative purchase of 2,000 shares on 08/14/2025 at a price of $40.8935 per share, increasing his direct beneficial ownership to 20,376 shares. The Form 4 was signed by an attorney-in-fact on 08/18/2025. No derivative transactions or additional remarks were reported.
Insider purchase disclosed: Celanese Corporation director Ganesh Moorthy bought 1,000 shares of CE common stock on 08/14/2025 at a reported price of $40.942 per share, increasing his direct holdings to 6,015 shares. The filing also shows an indirect holding of 3,000 shares held by the Ganesh and Hema Moorthy Revocable Living Trust. The Form 4 was signed by an attorney-in-fact on 08/18/2025.
Edward G. Galante, a director of Celanese Corporation (CE), reported a sale of company common stock on 08/14/2025. The Form 4 shows 2,400 shares were disposed of at a weighted-average price of $41.272 per share, with prices in the range $40.98 to $41.45. After the reported transaction, Mr. Galante beneficially owned 21,377 shares. The filing was signed by an attorney-in-fact on 08/18/2025 and notes the seller can provide exact per-transaction quantities on request.
Insider transaction reported by Celanese director Kim K.W. Rucker. The Form 4 records a derivative acquisition dated 08/11/2025: phantom stock units were recorded as acquired (transaction code A). The filing shows numeric values of 9,506.8 and a price figure of $47.42 in the derivative table. The form clarifies that each phantom share represents the right to receive one share of Celanese common stock and that these phantom shares reflect dividend equivalents credited under the company’s 2008 Deferred Compensation Plan.
The phantom shares become payable in common stock following the director’s termination of service, per the plan language included in the filing. The report was signed by an attorney-in-fact on 08/13/2025 and identifies Rucker as a director of Celanese (CE). The form does not provide additional context such as immediate share transfers, sales, or changes to direct holdings apart from the deferred compensation disclosure.
Deborah J. Kissire, a director of Celanese Corporation (CE), reported an acquisition of phantom stock on 08/11/2025 under the companys 2008 Deferred Compensation Plan. Each phantom share represents the right to receive one share of Celanese common stock. The filing lists 5,916.748 underlying shares and shows a referenced price of $47.42. The phantom shares represent dividend equivalents on compensation deferred under the Plan and become payable in common stock following the termination of Kissires service as a director.
The Form 4 was signed by an attorney-in-fact on 08/13/2025. The transaction is coded as an acquisition (A) of phantom stock rather than a sale or open-market trade, and the reporting person is identified as a director of the issuer.
Celanese Corporation director Jay V. Ihlenfeld reported an acquisition of phantom stock units tied to the company’s common shares. The Form 4 shows a transaction dated 08/11/2025 in which 10,227.219 units of phantom stock were acquired, with an associated figure of $47.42 shown in the table. Each phantom stock unit represents the right to receive one share of Celanese common stock.
These phantom units are described as dividend equivalents under the company’s 2008 Deferred Compensation Plan and are payable in shares of common stock as provided by the Plan following the termination of the reporting person’s service as a director. The filing identifies Ihlenfeld as a director and the Form is filed by one reporting person.
Kathryn Hill, a director of Celanese Corporation (CE), reported an acquisition of phantom stock units on 08/11/2025 on a Form 4 filing. The filing records the acquisition as dividend equivalents credited under the Company’s 2008 Deferred Compensation Plan; each phantom stock unit represents the right to receive one share of Celanese common stock and becomes payable in shares following termination of the director’s service.
The Form 4 shows a transaction entry of 1.86 (associated with the phantom stock), an indicated price of $47.42, and a post-transaction beneficial ownership figure of 2,946.61 derivative securities reported as held directly. The filing is signed by Christine Dryden as attorney-in-fact on 08/13/2025.
Celanese Corporation director Timothy Go was credited on 08/11/2025 with phantom stock units under the company’s 2008 Deferred Compensation Plan. Each phantom unit represents the right to receive one share of Celanese common stock, and the reported units are dividend equivalents that become payable in shares following the termination of the reporting person’s service. The Form 4 shows an allocation of 0.71 phantom shares at an indicated value of $47.42, bringing total reported phantom holdings to 1,114.71 units, reported as direct ownership. The entry is recorded in Table II as a derivative securities acquisition and reflects non-cash, deferred compensation rather than an open-market trade.
FAQ
What is the current stock price of Celanese Del (CE)?
What is the market cap of Celanese Del (CE)?
